keyword
MENU ▼
Read by QxMD icon Read
search

drug adverse events

keyword
https://www.readbyqxmd.com/read/29909472/the-impact-of-5%C3%AE-reductase-inhibitor-use-for-male-pattern-hair-loss-on-men-s-health
#1
REVIEW
Mohammed A Said, Akanksha Mehta
PURPOSE OF REVIEW: Male pattern hair loss, mediated by dihydrotestosterone, is a common hair loss disorder, affecting over 50% of men over the age of 50. The 5-α reductase inhibitors, finasteride and dutasteride, are Food and Drug Administration-approved drugs for the treatment of this disorder. Several recent studies have reported adverse sexual and spermatogenic events among young men using 5-α reductase inhibitors, such as erectile dysfunction, decreased ejaculate volume, decreased libido, and infertility...
June 16, 2018: Current Urology Reports
https://www.readbyqxmd.com/read/29909432/pharmacokinetics-of-a-novel-sildenafil-orodispersible-film-administered-by-the-supralingual-and-the-sublingual-route-to-healthy-men
#2
Luca Loprete, Chiara Leuratti, Valeria Frangione, Milko Radicioni
BACKGROUND: Sildenafil was the first selective drug available on the market as oral therapy for erectile dysfunction (ED). A novel sildenafil orodispersible film (ODF) for ED treatment, containing sildenafil citrate, has recently been marketed. OBJECTIVES: Study objective was to investigate sildenafil bioavailability of the novel ODF formulation after sublingual and supralingual administration. METHODS: In this randomised, two-way cross-over study, 12 healthy male volunteers received a single 50 mg sildenafil dose by the sublingual and supralingual administration routes...
June 16, 2018: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29909069/antimalarial-activity-of-single-dose-dsm265-a-novel-plasmodium-dihydroorotate-dehydrogenase-inhibitor-in-patients-with-uncomplicated-plasmodium-falciparum-or-plasmodium-vivax-malaria-infection-a-proof-of-concept-open-label-phase-2a-study
#3
Alejandro Llanos-Cuentas, Martin Casapia, Raúl Chuquiyauri, Juan-Carlos Hinojosa, Nicola Kerr, Maria Rosario, Stephen Toovey, Robert H Arch, Margaret A Phillips, Felix D Rozenberg, Jade Bath, Caroline L Ng, Annie N Cowell, Elizabeth A Winzeler, David A Fidock, Mark Baker, Jörg J Möhrle, Rob Hooft van Huijsduijnen, Nathalie Gobeau, Nada Araeipour, Nicole Andenmatten, Thomas Rückle, Stephan Duparc
BACKGROUND: DSM265 is a novel, long-duration inhibitor of plasmodium dihydroorotate dehydrogenase (DHODH) with excellent selectivity over human DHODH and activity against blood and liver stages of Plasmodium falciparum. This study aimed to assess the efficacy of DSM265 in patients with P falciparum or Plasmodium vivax malaria infection. METHODS: This proof-of-concept, open-label, phase 2a study was conducted at the Asociación Civil Selva Amazónica in Iquitos, Peru...
June 13, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29908761/health-related-quality-of-life-after-bleeding-adverse-events-associated-with-antithrombotic-drug-therapy-a-systematic-review
#4
REVIEW
Lodewijk C S Res, Bart Lubberts, Shivesh H Shah, Christopher W DiGiovanni
BACKGROUND: Little is known about the health-related quality of life (HRQOL) following adverse bleeding events associated with antithrombotic drug therapy. This systematic review assesses the HRQOL of patients who suffered a bleeding event related to antithrombotic drug use. METHODS: Literature search was performed using PubMed, EMBASE, and the Cochrane Library from inception through June 16, 2017. Studies measuring HRQOL after a bleeding event related to antithrombotic drug therapy for primary or secondary prevention of a thromboembolic event were included...
June 14, 2018: Hellenic Journal of Cardiology: HJC, Hellēnikē Kardiologikē Epitheōrēsē
https://www.readbyqxmd.com/read/29908670/safety-and-efficacy-of-upadacitinib-in-patients-with-active-rheumatoid-arthritis-refractory-to-biologic-disease-modifying-anti-rheumatic-drugs-select-beyond-a-double-blind-randomised-controlled-phase-3-trial
#5
Mark C Genovese, Roy Fleischmann, Bernard Combe, Stephen Hall, Andrea Rubbert-Roth, Ying Zhang, Yijie Zhou, Mohamed-Eslam F Mohamed, Sebastian Meerwein, Aileen L Pangan
BACKGROUND: Phase 2 studies with upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, have shown safety and efficacy in the treatment of patients with active rheumatoid arthritis. We did this study to further assess the safety and efficacy of upadacitinib in patients with an inadequate response to biologic disease-modifying anti-rheumatic drugs (bDMARDs). METHODS: We did this double-blind, randomised controlled phase 3 trial at 153 sites in 26 countries. Patients were aged 18 years or older, had active rheumatoid arthritis and previous inadequate response or intolerance to bDMARDs, and were receiving concomitant background conventional synthetic DMARDS (csDMARDs)...
June 12, 2018: Lancet
https://www.readbyqxmd.com/read/29908669/safety-and-efficacy-of-upadacitinib-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-conventional-synthetic-disease-modifying-anti-rheumatic-drugs-select-next-a-randomised-double-blind-placebo-controlled-phase-3-trial
#6
Gerd R Burmester, Joel M Kremer, Filip Van den Bosch, Alan Kivitz, Louis Bessette, Yihan Li, Yijie Zhou, Ahmed A Othman, Aileen L Pangan, Heidi S Camp
BACKGROUND: Upadacitinib is a selective inhibitor of Janus kinase 1 and was efficacious in phase 2 studies in patients with moderate-to-severe rheumatoid arthritis. We aimed to assess the efficacy of upadacitinib in patients with inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). METHODS: This study is a double-blind, placebo-controlled trial at 150 sites in 35 countries. We enrolled patients aged 18 years or older with active rheumatoid arthritis for 3 months or longer, who had received csDMARDs for at least 3 months with a stable dose for at least 4 weeks before study entry, and had an inadequate response to at least one of the following csDMARDs: methotrexate, sulfasalazine, or leflunomide...
June 12, 2018: Lancet
https://www.readbyqxmd.com/read/29907425/repurposing-steroidogenesis-inhibitors-for-the-therapy-of-neuropsychiatric-disorders-promises-and-caveats
#7
REVIEW
Roberto Frau, Marco Bortolato
Steroids exert a profound influence on behavioral reactivity, by modulating the functions of most neurotransmitters and shaping the impact of stress and sex-related variables on neural processes. This background - as well as the observation that most neuroactive steroids (including sex hormones, glucocorticoids and neurosteroids) are synthetized and metabolized by overlapping enzymatic machineries - points to steroidogenic pathways as a powerful source of targets for neuropsychiatric disorders. Inhibitors of steroidogenic enzymes have been developed and approved for a broad range of genitourinary and endocrine dysfunctions, opening to new opportunities to repurpose these drugs for the treatment of mental problems...
May 11, 2018: Neuropharmacology
https://www.readbyqxmd.com/read/29907124/exon-skipping-for-duchenne-muscular-dystrophy-a-systematic-review-and-meta-analysis
#8
Yuko Shimizu-Motohashi, Terumi Murakami, En Kimura, Hirofumi Komaki, Norio Watanabe
BACKGROUND: Exon skipping has been considered a promising therapeutic approach for Duchenne muscular dystrophy (DMD). Eteplirsen received conditional approval in the United States in 2016. To date, no systematic reviews or meta-analyses of randomized controlled trials (RCTs) of exon skipping drugs have been published to determine the pooled estimates for the effect of exon skipping in treating DMD. METHODS: A systematic review and meta-analysis of double-blind RCTs comparing exon-skipping drugs with placebo in DMD was performed...
June 15, 2018: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/29907117/increasing-evidence-of-low-lymphatic-filariasis-prevalence-in-high-risk-loa-loa-areas-in-central-and-west-africa-a-literature-review
#9
REVIEW
Louise A Kelly-Hope, Janet Hemingway, Mark J Taylor, David H Molyneux
In West and Central Africa, there is a need to establish the prevalence of Wuchereria bancrofti in areas that are co-endemic for Loa loa, in order to implement the appropriate strategies to scale-up interventions for the elimination of lymphatic filariasis (LF). Due to the risk of severe adverse events (SAEs) to ivermectin in individuals with high L. loa microfilaraemia, the current strategy recommended by the World Health Organization (WHO) is twice yearly mass drug administration (MDA) with albendazole, supplemented by vector control targeting the Anopheles vectors...
June 15, 2018: Parasites & Vectors
https://www.readbyqxmd.com/read/29906795/national-survey-of-neonatal-intensive-care-unit-medication-safety-practices
#10
Rachel G Greenberg, P Brian Smith, Carl Bose, Reese H Clark, C Michael Cotten, Chris DeRienzo
OBJECTIVE:  We conducted a detailed survey to identify medication safety practices among a large network of United States neonatal intensive care units (NICUs). METHODS:  We created a 53-question survey to assess 300 U.S. NICU's demographics, medication safety practices, adverse drug event (ADE) reporting, and ADE response plans. RESULTS:  Among the 164 (55%) NICUs that responded to the survey, more than 85% adhered to practices including use of electronic health records, computerized physician order entry, and clinical decision support; fewer reported adopting barcoding, formal safety surveys, and formal culture training; 137 of 164 (84%) developed at least one NICU-specific order-set with a median of 10 order-sets...
June 15, 2018: American Journal of Perinatology
https://www.readbyqxmd.com/read/29906601/sofosbuvir-in-combination-with-daclatasvir-or-simeprevir-for-12-weeks-in-non-cirrhotic-subjects-chronically-infected-with-hepatitis-c-virus-genotype-1-a-randomized-clinical-trial
#11
Henrique Pott Junior, Guilherme Bricks, Giuliano Grandi, Jorge Figueiredo Senise, Adauto Castelo Filho
OBJECTIVES: This study aimed to investigate the efficacy and safety of sofosbuvir plus daclatasvir (SOF+DCV) or simeprevir (SOF+SMV) in a randomized, open-label, non-inferiority trial of patients infected with hepatitis c virus (HCV) genotype 1, who were previously unresponsive to pegylated interferon and ribavirin or were treatment-naïve. METHODS: Patients were randomly assigned to receive SOF (400 mg once daily) plus DCV (60 mg once daily) or SMV (150 mg once daily) for 12 weeks...
June 12, 2018: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29906567/assessment-of-posaconazole-salvage-therapy-in-chronic-pulmonary-aspergillosis-by-using-predefined-response-criteria
#12
Isabel Rodriguez-Goncer, Chris Harris, Chris Kosmidis, Eavan G Muldoon, Pippa J Newton, David W Denning
OBJECTIVE: Chronic pulmonary aspergillosis (CPA) is a progressive infection that destroys lung tissue in non-immunocompromised patients. First line therapies for CPA (itraconazole and/or voriconazole) are often curtailed due to toxicity or the development of drug resistance. Posaconazole is a potential alternative for these patients. METHODS: Use of posaconazole was funded by the NHS Highly Specialised National Commissioners on an individual basis for patients who failed or did not tolerate first line therapy; those who met predefined criteria for improvement at 4 and 6 months (weight gain and/or improvement in St George's Respiratory Questionnaire) continued posaconazole long-term...
June 12, 2018: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/29906525/treatment-of-atopic-dermatitis-with-tralokinumab-an-anti-il-13-monoclonal-antibody
#13
Andreas Wollenberg, Michael D Howell, Emma Guttman-Yassky, Jonathan I Silverberg, Christopher Kell, Koustubh Ranade, Rachel Moate, René van der Merwe
BACKGROUND: Interleukin (IL)-13 has an important role in atopic dermatitis (AD) pathogenesis. Tralokinumab is a fully human monoclonal antibody that potently and specifically neutralizes IL-13. OBJECTIVE: To evaluate the efficacy and safety of tralokinumab in adults with moderate to severe AD. METHODS: In this phase 2b study (NCT02347176), 204 adults were randomized 1:1:1:1 to receive subcutaneous tralokinumab 45 mg, 150 mg, or 300 mg, or placebo, every 2 weeks for 12 weeks, with concomitant topical glucocorticoids...
June 12, 2018: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29906311/elderly-psoriatic-patients-under-biological-therapies-an-italian-experience
#14
F Ricceri, F Bardazzi, A Chiricozzi, P Dapavo, F Ferrara, C Mugheddu, M Romanelli, F Rongioletti, F Prignano
BACKGROUND: The number elderly patients with psoriasis is steadily increasing in the Western world, nevertheless they are frequently excluded from biologic clinical trials and described as a high-risk group for adverse events. Thus, there is lack of information concerning safety and effectiveness of available treatments for psoriasis in the elderly, particularly about new biologic systemic drugs. OBJECTIVE: Our aim is to describe our experience with all biological therapies currently used in the elderly (> 65 years) psoriatic patients...
June 15, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29906006/topical-application-of-5-fluorouracil-5-percent-cream-associated-with-severe-neutropenia-discussion-of-a-case-and-review-of-systemic-reactions-after-topical-treatment-with-5-fluorouracil
#15
Philip R Cohen
5-fluorouracil, a fluoropyrimidine antineoplastic drug, is used to topically treat actinic keratoses. Local skin reactions to the medication are common and anticipated. However, severe adverse events from topical 5-fluorouracil are rare and unexpected. A 69-year-old man with a lower lip actinic keratosis developed severe neutropenia on day 11 of topical 5-fluorouracil treatment - after 14 applications. After receiving a subcutaneous injection of filgrastim, his neutrophil count normalized. The PubMed database was used to search the following terms: agranulocytosis, cream, 5-fluorouracil, granulocytopenia, neutropenia, severe, systemic, topical, and toxicity...
April 15, 2018: Dermatology Online Journal
https://www.readbyqxmd.com/read/29905977/inspiromatic-safety-and-efficacy-study-of-a-new-generation-dry-powder-inhaler-in-asthmatic-children
#16
Guy Steuer, Dario Prais, Huda Mussaffi, Meir Mei-Zahav, Ophir Bar-On, Hagit Levine, Yulia Gendler, Hannah Blau, Patrick Stafler
BACKGROUND: Dry powder inhalers (DPI) are effective but forceful inhalation required to fluidize the powder may be difficult for children and patients with airway disease. Inspiromatic is a new generation active DPI that actively suspends drugs in synchrony with inhalation. We evaluated safety and efficacy of Formoterol delivery via Inspiromatic, compared to Aerolizer, a conventional DPI, in pediatric asthmatic subjects. METHODS: A phase I/II, randomized, single-center, double-blind, double-dummy, placebo-controlled, cross-over study...
June 15, 2018: Pediatric Pulmonology
https://www.readbyqxmd.com/read/29905976/pharmacokinetics-safety-and-tolerability-of-rolapitant-administered-intravenously-following-single-ascending-and-multiple-ascending-doses-in-healthy-subjects
#17
Xiaodong Wang, Zhi-Yi Zhang, Jing Wang, Dan Powers, Sujata Arora, Sharon Lu, Vikram Kansra
Rolapitant is a selective and long-acting neurokinin-1 receptor antagonist approved in an oral formulation in combination with dexamethasone and a 5-hydroxytryptamine type 3 receptor antagonist for the prevention of delayed chemotherapy-induced nausea and vomiting in adults. The pharmacokinetic and safety profiles of intravenous (IV) rolapitant were evaluated in two open-label, phase 1 trials in healthy subjects. Single ascending dose (SAD) and multiple ascending dose studies were conducted in one trial (PR-11-5012-C), and a supratherapeutic SAD study was conducted in a separate trial (PR-11-5022-C)...
June 15, 2018: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/29905919/sexual-behaviors-experiences-of-sexual-violence-and-substance-use-among-women-who-inject-drugs-accessing-health-and-prevention-services-in-puerto-rico
#18
Erika M Collazo-Vargas, Brian Dodge, Debby Herbenick, Lucia Guerra-Reyes, Rasul Mowatt, Ilia M Otero-Cruz, Carlos Rodríguez-Díaz
OBJECTIVE: People who inject drugs (PWID) face numerous gender-specific health risks, which increase their susceptibility to adverse outcomes, including violence. There is a need for research on female PWID to capture their unique experiences and understand behavioral and gender-based differences. This study aimed to understand which drug use and sexual behaviors are the most prevalent among female PWID accessing health services in Puerto Rico and to gather preliminary information on those individuals' experiences of sexual violence...
June 2018: Puerto Rico Health Sciences Journal
https://www.readbyqxmd.com/read/29905619/pharmacokinetic-comparison-of-two-mycophenolate-mofetil-formulations-in-kidney-transplant-recipients
#19
Jun Zhang, YongGang Luo, ZhenFeng Zhu, GuiWen Feng, Zhi Sun, XiaoJian Zhang
BACKGROUND: The aim of this study was to investigate and compare the pharmacokinetic (PK) characteristics of mycophenolate mofetil (MMF) capsule and MMF dispersible tablet by detecting the active metabolite of mycophenolic acid (MPA) in Chinese kidney transplant recipients. METHODS: In the prospective, randomized, open-label study, the renal transplant patients were given a multiple-dose of either MMF capsule or MMF dispersible tablet combination with tacrolimus (Tac)...
June 12, 2018: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/29905384/clindamycin-phosphate-1-2-benzoyl-peroxide-3-fixed-dose-combination-gel-versus-topical-combination-therapy-of-adapalene-0-1-gel-and-clindamycin-phosphate-1-2-gel-in-the-treatment-of-acne-vulgaris-in-japanese-patients-a-multicenter-randomized-investigator-blind
#20
Nobukazu Hayashi, Ichiro Kurokawa, Obukohwo Siakpere, Akira Endo, Toshiki Hatanaka, Masahiro Yamada, Makoto Kawashima
Adapalene 0.1% (ADA) with clindamycin phosphate 1.2% (CLNP; ADA + CLNP) and the fixed-dose combination containing CLNP and benzoyl peroxide 3% (CLNP/BPO 3%) are strongly recommended for the early treatment of acne vulgaris in Japan. Here, we compare the early efficacy and safety of CLNP/BPO 3% with Japanese standard topical use of ADA + CLNP in the treatment of acne vulgaris. In this phase IV, multicenter study, 351 patients were randomized to receive CLNP/BPO 3% or ADA + CLNP for 12 weeks. The primary end-point was percentage change from baseline in total lesion (TL) counts at week 2...
June 15, 2018: Journal of Dermatology
keyword
keyword
40867
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"